ApoA1 Trial Misses Endpoint, But HDL Hypothesis Still Alive?

ApoA1 infusions in acute MI did not significantly reduce the composite endpoint in the AEGIS-II trial. However, an exploratory analysis suggested benefit at higher LDL levels.
Medscape Medical News

source https://www.medscape.com/viewarticle/apoa1-trial-misses-endpoint-hdl-hypothesis-still-alive-2024a10006km?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost